 |
|
|
| |
Predictors of Sustained Virologic Response Among Genotype 1 Previous Non-Responders and Relapsers to Peginterferon/Ribavirin When Re-Treated With Boceprevir Plus Peginterferon Alfa-2b/Ribavirin (IL28B affect-see bargraph inside)
|
| |
| |
Reported by Jules Levin
EASL 2011 March 30-Apr 2 Berlin Germany
S. Zeuzem1*, J.M. Vierling2, R. Esteban3, A.L. Gibas4, S. Pol5, N. Ruiyan Jiang6, M. Burroughs6, C.A. Brass6, J.K. Albrecht6, F. Poordad7
1JW Goethe University Hospital, Frankfurt/Main, Germany, 2Baylor College of Medicine, Houston, TX, USA, 3Vall d'Hebron Hospital, Barcelona, Spain, 4Regional Gastroenterology Associates of Lancaster, Lancaster, PA, USA, 5Hopital Necker, Paris, France, 6Merck Sharp & Dohme Corp., Whitehouse Station, NJ, USA, 7Cedars-Sinai Medical Center, Los Angeles, CA, USA. *zeuzem@em.uni-frankfurt.d
PR 4 Week Lead-In as a Predictor of SVR:
A <1 log10 decline in viral load after the 4-week P/R lead-in was observed in 26% (102/393) of patients - 33-34% of these patients achieved SVR when BOC was added to standard of care, compared with 0% in patients retreated with P/R (Figure 3). 75% with >1 log viral load reduction at week achieved SVR vs 34% of patients with <1 log viral load reduction at week 4.
Here are the 2 analyses from this study regarding the predictability of IL28B, the 1st graph below is from this poster analysis & the 2nd below from the Poordad oral presentation with a link to it below: it appears to me that in the 2nd Figure below it shows that CC shows the best predictability in the BOC RGT arm and thats because if you read the oral presentation by Poordad by clicking the lick below CC patients have better early responses and therefore they are more likely to be able to stop therapy earlier. So with the use of boceprevir one can say I think that if a person is a CC they are more likely to be able to only have to take shortened therapy.
EASL: IL28B POLYMORPHISM PREDICTS VIROLOGIC RESPONSE IN PATIENTS WITH HEPATITIS C GENOTYPE 1 TREATED WITH BOCEPREVIR COMBINATION THERAPY - (04/01/11)
|
| |
|
|
|
|
|
